UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July~~December 3012, 2013

ALSERES PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	0-6533	87-0277826
(State or Other Jurisdictionof Incorporation	(CommissionFile Number)	(IRS EmployerIdentification No.)
(State or Other Jurisdiction of Incorporation	(Commission File Number)	(IRS Employer Identification No.)
239 South Street, Hopkinton, Massachusetts		01748
(Address of Principal Executive Offices)		(Zip Code)


239 South Street, Hopkinton, Massachusetts		01748
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (508) 497-2360

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 1.01. Entry into Material Definitive Agreements			3
SIGNATURE			3

Item 1.01. Entry into Material Definitive Agreements

SIGNATURE

-2-

Item 1.01. Entry into Material. Definitive Agreements.

On ~~May~~July 231, 2012 ~~the~~we ~~Company~~executed ~~received~~a ~~notice~~License ~~that~~Agreement ~~Biostorage~~with ~~Technologies,~~Navidea ~~Inc~~under ~~(Biostorage).~~which ~~had~~we ~~filed~~granted aNavidea ~~lawsuit~~an ~~in Marion Superior/Circuit Court~~exclusive, ~~Marion~~ ~~County,~~worldwide ~~Indiana~~sublicense ~~seeking~~ to ~~recover~~research, ~~amounts alleged to be owed by the Company to the plaintiffs totaling $119~~develop,~~363~~ ~~plus legal fees~~ and commercialize ~~costs~~Altropane. OnIn ~~July 30,~~connection ~~2013~~with the ~~Company~~execution ~~entered~~of ~~into~~this ~~a settlement and release~~ agreement ~~with BioStorage Technologies~~, ~~Inc.~~Navidea ~~(“BioStorage”)~~made ~~pursuant~~a toone-time ~~which~~sublicense ~~the~~execution ~~Company~~payment ~~agreed~~ to ~~make~~us 3equal ~~payments~~to ~~totaling~~(i) One ~~seventy~~Hundred ~~five~~Seventy-Five ~~thousand~~Thousand ~~dollars~~Dollars ($75175,000~~.00~~) inand ~~full~~(ii) issued ~~settlement~~us of300,000 ~~the~~shares ~~claims~~of NAVB ~~against~~common ~~the Company~~stock. ~~The agreement calls for three payments to be made as follows:~~

The license agreement also provided for contingent milestone payments of up to $102.9 million,~~000~~ $2.005 onmillion of which will principally occur at the time of product registration or ~~before~~upon ~~July~~commercial sales, and the issuance of up to an additional 1.15 31million shares of Navidea stock, ~~2013~~950,000 shares of which are issuable at the time of product registration or upon commercial sales.

On December 12, 2013 we were notified that Navidea had enrolled the first patient in a Phase III clinical trial of Altropane in the United States resulting in the payment of the cash sum of $40200,000~~.00~~ onto orus ~~before~~and ~~December 31~~in the issuance of 100,000 ~~2013~~shares ~~and’~~of Navidea common stock to us.

~~$25~~Pursuant to the requirements of the Securities Exchange Act of 1934,~~000.00~~ the Registrant has duly caused this report to be signed on orits ~~before~~behalf ~~February 28,~~by ~~2014~~the undersigned hereunto duly authorized.

As part of the settlement agreement and in the event that the Company fails to honor its obligations under the settlement agreement, the Company executed an agreed judgment in the total amount of $95,000.00 such amount to be reduced by the amount of each scheduled payment actually made by the Company pursuant to the settlement agreement.


	Alseres Pharmaceuticals, Inc.

Date: December 17, 2013	By:	/s/ Kenneth L. Rice, Jr.
		Kenneth L. Rice, Jr.
		Executive Vice President, Finance and Administration and Chief Financial Officer

~~Pursuant~~-3- ~~to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~

-3-

Alseres Pharmaceuticals, Inc.

Date: July 31, 2013

/s/ Kenneth L. Rice, Jr.

Kenneth L. Rice, Jr.

Executive Vice President, Finance andAdministration and Chief Financial Officer

Filing Compare · ALSERES PHARMACEUTICALS INC /DE